| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 207 | 2023 | 5061 | 12.740 |
Why?
|
| Carcinoma, Pancreatic Ductal | 91 | 2023 | 1724 | 8.710 |
Why?
|
| Pancreatectomy | 43 | 2021 | 652 | 5.610 |
Why?
|
| Adenocarcinoma | 80 | 2023 | 7789 | 4.160 |
Why?
|
| Pancreaticoduodenectomy | 50 | 2022 | 690 | 3.860 |
Why?
|
| Lumican | 5 | 2018 | 22 | 2.510 |
Why?
|
| Pancreatic Stellate Cells | 4 | 2022 | 76 | 1.950 |
Why?
|
| Deoxycytidine | 24 | 2019 | 1353 | 1.900 |
Why?
|
| Heterografts | 11 | 2020 | 733 | 1.710 |
Why?
|
| Neoadjuvant Therapy | 47 | 2023 | 4975 | 1.700 |
Why?
|
| Autophagy | 7 | 2018 | 927 | 1.390 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 17 | 2023 | 1331 | 1.380 |
Why?
|
| Common Bile Duct Neoplasms | 10 | 2017 | 145 | 1.380 |
Why?
|
| Tumor Microenvironment | 9 | 2023 | 2864 | 1.370 |
Why?
|
| Ampulla of Vater | 10 | 2017 | 155 | 1.260 |
Why?
|
| Neuroendocrine Tumors | 10 | 2019 | 634 | 1.260 |
Why?
|
| Antimetabolites, Antineoplastic | 9 | 2019 | 1299 | 1.260 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2023 | 10035 | 1.150 |
Why?
|
| Humans | 276 | 2023 | 261506 | 1.110 |
Why?
|
| Portal Vein | 8 | 2018 | 355 | 1.090 |
Why?
|
| Mesenteric Artery, Superior | 4 | 2015 | 71 | 1.050 |
Why?
|
| Pancreatic Cyst | 7 | 2012 | 107 | 1.050 |
Why?
|
| Chemotherapy, Adjuvant | 24 | 2021 | 3890 | 1.020 |
Why?
|
| Smad4 Protein | 8 | 2018 | 196 | 0.980 |
Why?
|
| Discoidin Domain Receptor 1 | 2 | 2021 | 16 | 0.970 |
Why?
|
| Critical Pathways | 2 | 2021 | 149 | 0.930 |
Why?
|
| Xenograft Model Antitumor Assays | 19 | 2021 | 3821 | 0.910 |
Why?
|
| Chemoradiotherapy, Adjuvant | 11 | 2021 | 565 | 0.910 |
Why?
|
| Chemoradiotherapy | 16 | 2022 | 1946 | 0.910 |
Why?
|
| Lymph Nodes | 10 | 2016 | 2967 | 0.910 |
Why?
|
| Mesenteric Veins | 5 | 2018 | 73 | 0.900 |
Why?
|
| Mice | 69 | 2023 | 34495 | 0.870 |
Why?
|
| Gastrointestinal Neoplasms | 5 | 2022 | 600 | 0.870 |
Why?
|
| Neoplasm Transplantation | 11 | 2018 | 1519 | 0.860 |
Why?
|
| Fluorouracil | 13 | 2021 | 1944 | 0.820 |
Why?
|
| Endosonography | 6 | 2013 | 536 | 0.810 |
Why?
|
| Asparagine | 1 | 2021 | 38 | 0.810 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 2021 | 21 | 0.800 |
Why?
|
| Neoplasm Staging | 48 | 2022 | 13658 | 0.800 |
Why?
|
| Cell Line, Tumor | 37 | 2023 | 14551 | 0.800 |
Why?
|
| Extracellular Traps | 1 | 2021 | 25 | 0.800 |
Why?
|
| Cell Proliferation | 25 | 2021 | 7226 | 0.790 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2021 | 60 | 0.790 |
Why?
|
| Aged | 109 | 2023 | 70117 | 0.780 |
Why?
|
| Mice, Inbred NOD | 11 | 2021 | 905 | 0.780 |
Why?
|
| Middle Aged | 119 | 2021 | 86204 | 0.780 |
Why?
|
| Laparoscopy | 12 | 2021 | 1225 | 0.780 |
Why?
|
| Neoplasms, Experimental | 3 | 2021 | 750 | 0.780 |
Why?
|
| Survival Rate | 34 | 2021 | 12221 | 0.770 |
Why?
|
| Animals | 79 | 2023 | 59536 | 0.770 |
Why?
|
| Preoperative Care | 10 | 2022 | 1529 | 0.770 |
Why?
|
| Liver Neoplasms | 12 | 2022 | 4557 | 0.740 |
Why?
|
| Male | 137 | 2022 | 123000 | 0.740 |
Why?
|
| Mice, SCID | 13 | 2021 | 1869 | 0.730 |
Why?
|
| Female | 141 | 2022 | 141928 | 0.720 |
Why?
|
| Hepatic Stellate Cells | 1 | 2020 | 30 | 0.720 |
Why?
|
| Neutrophils | 2 | 2021 | 835 | 0.720 |
Why?
|
| Retrospective Studies | 66 | 2023 | 37905 | 0.700 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2017 | 690 | 0.690 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 249 | 0.690 |
Why?
|
| Prognosis | 56 | 2022 | 21713 | 0.680 |
Why?
|
| Genistein | 2 | 2019 | 73 | 0.670 |
Why?
|
| Aged, 80 and over | 65 | 2021 | 29902 | 0.670 |
Why?
|
| Combined Modality Therapy | 25 | 2018 | 8865 | 0.670 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2023 | 15862 | 0.660 |
Why?
|
| Phosphatidylserines | 2 | 2017 | 68 | 0.650 |
Why?
|
| Pancreatic Ducts | 6 | 2018 | 122 | 0.640 |
Why?
|
| Tomography, X-Ray Computed | 22 | 2019 | 7551 | 0.640 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 1225 | 0.640 |
Why?
|
| Pancreas | 11 | 2023 | 718 | 0.630 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2011 | 229 | 0.630 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 53 | 0.580 |
Why?
|
| Biomarkers, Tumor | 21 | 2022 | 10331 | 0.580 |
Why?
|
| Camptothecin | 2 | 2016 | 517 | 0.570 |
Why?
|
| Lymph Node Excision | 6 | 2017 | 1959 | 0.560 |
Why?
|
| Mice, Nude | 17 | 2021 | 4307 | 0.560 |
Why?
|
| Neoplasm Invasiveness | 17 | 2017 | 3981 | 0.560 |
Why?
|
| Tumor Burden | 11 | 2021 | 1987 | 0.560 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 134 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2021 | 8873 | 0.530 |
Why?
|
| Disease-Free Survival | 25 | 2021 | 10001 | 0.530 |
Why?
|
| CA-19-9 Antigen | 5 | 2020 | 144 | 0.520 |
Why?
|
| Postoperative Care | 3 | 2016 | 739 | 0.520 |
Why?
|
| Keratan Sulfate | 1 | 2014 | 11 | 0.510 |
Why?
|
| Adult | 82 | 2021 | 77950 | 0.510 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2014 | 38 | 0.510 |
Why?
|
| Carcinogenesis | 6 | 2021 | 1026 | 0.500 |
Why?
|
| Neoplasm Metastasis | 12 | 2021 | 5112 | 0.500 |
Why?
|
| Hepatectomy | 6 | 2022 | 1011 | 0.500 |
Why?
|
| Apoptosis | 11 | 2021 | 7591 | 0.490 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 204 | 0.490 |
Why?
|
| Genetic Therapy | 2 | 2017 | 1616 | 0.490 |
Why?
|
| Radiotherapy, Adjuvant | 12 | 2015 | 2231 | 0.480 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 524 | 0.480 |
Why?
|
| Signal Transduction | 28 | 2023 | 11965 | 0.480 |
Why?
|
| Follow-Up Studies | 31 | 2020 | 14889 | 0.470 |
Why?
|
| Postoperative Complications | 16 | 2022 | 5542 | 0.470 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2017 | 343 | 0.470 |
Why?
|
| Kaplan-Meier Estimate | 22 | 2020 | 6207 | 0.470 |
Why?
|
| Jejunal Neoplasms | 1 | 2013 | 34 | 0.460 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2014 | 436 | 0.460 |
Why?
|
| Ileal Neoplasms | 1 | 2013 | 47 | 0.460 |
Why?
|
| Lymphatic Metastasis | 19 | 2017 | 4844 | 0.460 |
Why?
|
| Colorectal Neoplasms | 8 | 2023 | 3578 | 0.450 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2019 | 376 | 0.450 |
Why?
|
| Cell Culture Techniques | 2 | 2020 | 598 | 0.450 |
Why?
|
| Disease Management | 3 | 2020 | 1052 | 0.440 |
Why?
|
| Hepatic Artery | 2 | 2012 | 240 | 0.440 |
Why?
|
| Dysplastic Nevus Syndrome | 2 | 2009 | 50 | 0.440 |
Why?
|
| Transforming Growth Factor beta | 4 | 2016 | 1130 | 0.420 |
Why?
|
| Treatment Outcome | 44 | 2022 | 32848 | 0.420 |
Why?
|
| Water-Electrolyte Balance | 1 | 2012 | 104 | 0.410 |
Why?
|
| Antineoplastic Agents | 14 | 2021 | 14289 | 0.410 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2013 | 75 | 0.410 |
Why?
|
| Disease Models, Animal | 21 | 2020 | 7222 | 0.400 |
Why?
|
| Pancreatic Fistula | 3 | 2017 | 99 | 0.400 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 153 | 0.380 |
Why?
|
| Aneurysm, Ruptured | 1 | 2011 | 45 | 0.380 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2016 | 973 | 0.380 |
Why?
|
| Genes, ras | 5 | 2017 | 667 | 0.380 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 669 | 0.370 |
Why?
|
| Immunohistochemistry | 17 | 2019 | 7548 | 0.370 |
Why?
|
| Duodenal Neoplasms | 4 | 2017 | 138 | 0.370 |
Why?
|
| Intracranial Aneurysm | 1 | 2011 | 123 | 0.360 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2023 | 108 | 0.360 |
Why?
|
| Colonic Neoplasms | 6 | 2022 | 1390 | 0.360 |
Why?
|
| Blood Loss, Surgical | 3 | 2018 | 309 | 0.350 |
Why?
|
| Prospective Studies | 17 | 2021 | 12873 | 0.340 |
Why?
|
| Pancreatitis | 2 | 2009 | 267 | 0.340 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2017 | 476 | 0.330 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 2 | 2020 | 89 | 0.330 |
Why?
|
| Decision Support Techniques | 2 | 2013 | 622 | 0.320 |
Why?
|
| DNA, Neoplasm | 4 | 2021 | 1910 | 0.320 |
Why?
|
| Mesentery | 3 | 2020 | 72 | 0.320 |
Why?
|
| Glucose | 3 | 2021 | 1248 | 0.310 |
Why?
|
| Cell Movement | 8 | 2021 | 2466 | 0.310 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2017 | 992 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 12 | 2014 | 5395 | 0.310 |
Why?
|
| Neoplasm Grading | 6 | 2018 | 1742 | 0.310 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2008 | 69 | 0.300 |
Why?
|
| Blood Transfusion | 5 | 2018 | 583 | 0.300 |
Why?
|
| Splenic Vein | 2 | 2017 | 17 | 0.290 |
Why?
|
| NF-kappa B | 4 | 2016 | 1549 | 0.290 |
Why?
|
| Splenic Artery | 2 | 2017 | 50 | 0.290 |
Why?
|
| Population Surveillance | 4 | 2015 | 627 | 0.280 |
Why?
|
| Esophageal Neoplasms | 4 | 2022 | 3168 | 0.280 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2010 | 650 | 0.280 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2018 | 413 | 0.270 |
Why?
|
| Embolization, Therapeutic | 1 | 2011 | 551 | 0.270 |
Why?
|
| Risk Assessment | 14 | 2022 | 6869 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2019 | 5178 | 0.270 |
Why?
|
| Exercise Therapy | 2 | 2019 | 288 | 0.260 |
Why?
|
| Phenotype | 2 | 2014 | 6295 | 0.260 |
Why?
|
| Femoral Vein | 1 | 2005 | 66 | 0.260 |
Why?
|
| Mutation | 19 | 2023 | 15179 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 6 | 2017 | 945 | 0.260 |
Why?
|
| RNA, Messenger | 4 | 2015 | 6150 | 0.260 |
Why?
|
| Transplantation, Heterologous | 7 | 2014 | 1082 | 0.260 |
Why?
|
| Neovascularization, Pathologic | 5 | 2009 | 1547 | 0.250 |
Why?
|
| Peutz-Jeghers Syndrome | 2 | 2019 | 56 | 0.250 |
Why?
|
| Green Fluorescent Proteins | 4 | 2012 | 694 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2021 | 4757 | 0.250 |
Why?
|
| Survival Analysis | 14 | 2021 | 9180 | 0.250 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 1258 | 0.250 |
Why?
|
| Predictive Value of Tests | 10 | 2018 | 4892 | 0.250 |
Why?
|
| RNA | 3 | 2021 | 1013 | 0.250 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2016 | 716 | 0.250 |
Why?
|
| Immediate-Early Proteins | 1 | 2005 | 107 | 0.250 |
Why?
|
| Peritoneal Lavage | 1 | 2004 | 21 | 0.240 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 4298 | 0.240 |
Why?
|
| Carcinoma, Medullary | 3 | 2003 | 248 | 0.240 |
Why?
|
| Spleen | 2 | 2016 | 676 | 0.240 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2023 | 22 | 0.230 |
Why?
|
| Propensity Score | 4 | 2021 | 750 | 0.230 |
Why?
|
| DNA Adducts | 2 | 2014 | 210 | 0.230 |
Why?
|
| Radiosurgery | 2 | 2023 | 1330 | 0.230 |
Why?
|
| Burns | 1 | 2004 | 117 | 0.230 |
Why?
|
| Length of Stay | 5 | 2020 | 1900 | 0.230 |
Why?
|
| RNA, Small Interfering | 4 | 2016 | 2216 | 0.230 |
Why?
|
| Cancer Survivors | 2 | 2021 | 650 | 0.230 |
Why?
|
| Venous Thrombosis | 2 | 2018 | 384 | 0.230 |
Why?
|
| Cyclin D1 | 2 | 2017 | 576 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 6942 | 0.220 |
Why?
|
| MicroRNAs | 2 | 2017 | 2947 | 0.220 |
Why?
|
| Postoperative Hemorrhage | 3 | 2013 | 162 | 0.220 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2015 | 1064 | 0.220 |
Why?
|
| ras Proteins | 3 | 2013 | 770 | 0.220 |
Why?
|
| Carboxylesterase | 3 | 2021 | 33 | 0.220 |
Why?
|
| Multidetector Computed Tomography | 3 | 2013 | 150 | 0.220 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2015 | 551 | 0.220 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2020 | 275 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2023 | 1439 | 0.210 |
Why?
|
| STAT3 Transcription Factor | 2 | 2020 | 1121 | 0.210 |
Why?
|
| ErbB Receptors | 5 | 2022 | 2295 | 0.210 |
Why?
|
| Luminescent Proteins | 4 | 2014 | 289 | 0.210 |
Why?
|
| Risk Factors | 17 | 2019 | 17523 | 0.210 |
Why?
|
| Abdominal Neoplasms | 1 | 2004 | 231 | 0.210 |
Why?
|
| Clonal Evolution | 2 | 2021 | 253 | 0.210 |
Why?
|
| Quality Improvement | 4 | 2022 | 851 | 0.210 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2013 | 226 | 0.200 |
Why?
|
| Organoids | 2 | 2022 | 287 | 0.200 |
Why?
|
| Residence Characteristics | 2 | 2021 | 348 | 0.200 |
Why?
|
| Mitochondria | 3 | 2019 | 1282 | 0.200 |
Why?
|
| Cytidine Deaminase | 1 | 2021 | 83 | 0.200 |
Why?
|
| Extremities | 2 | 2001 | 303 | 0.200 |
Why?
|
| Proteolysis | 2 | 2021 | 370 | 0.200 |
Why?
|
| Fluorescent Dyes | 2 | 2014 | 459 | 0.200 |
Why?
|
| Elongation Factor 2 Kinase | 1 | 2021 | 44 | 0.200 |
Why?
|
| Mass Screening | 1 | 2009 | 1509 | 0.190 |
Why?
|
| Trans-Activators | 3 | 2003 | 1555 | 0.190 |
Why?
|
| Cell Survival | 5 | 2019 | 3045 | 0.190 |
Why?
|
| DNA-Binding Proteins | 4 | 2003 | 4821 | 0.190 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2019 | 299 | 0.190 |
Why?
|
| Medical Oncology | 3 | 2021 | 1423 | 0.190 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 3 | 2015 | 141 | 0.190 |
Why?
|
| Mucin-1 | 2 | 2019 | 127 | 0.190 |
Why?
|
| Patient Selection | 6 | 2021 | 2055 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 135 | 0.190 |
Why?
|
| Alternative Splicing | 1 | 2023 | 584 | 0.190 |
Why?
|
| SEER Program | 5 | 2019 | 1000 | 0.190 |
Why?
|
| Survivorship | 1 | 2021 | 109 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2013 | 2488 | 0.190 |
Why?
|
| Peritoneal Diseases | 1 | 2020 | 29 | 0.180 |
Why?
|
| Proportional Hazards Models | 9 | 2016 | 4988 | 0.180 |
Why?
|
| Biopsy | 5 | 2018 | 3443 | 0.180 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 76 | 0.180 |
Why?
|
| Lactic Acid | 2 | 2019 | 305 | 0.180 |
Why?
|
| Receptors, Peptide | 1 | 2020 | 86 | 0.180 |
Why?
|
| Stomach Neoplasms | 2 | 2021 | 2278 | 0.180 |
Why?
|
| General Surgery | 3 | 2015 | 326 | 0.180 |
Why?
|
| Phosphorylation | 6 | 2021 | 4804 | 0.180 |
Why?
|
| Genetic Heterogeneity | 2 | 2019 | 318 | 0.180 |
Why?
|
| Models, Biological | 5 | 2019 | 3254 | 0.180 |
Why?
|
| Sarcoma | 2 | 2001 | 1725 | 0.180 |
Why?
|
| Clinical Competence | 2 | 2020 | 1270 | 0.180 |
Why?
|
| Patient Readmission | 4 | 2018 | 548 | 0.180 |
Why?
|
| Time Factors | 16 | 2018 | 12926 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 657 | 0.180 |
Why?
|
| Disease Progression | 11 | 2021 | 6682 | 0.180 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2021 | 209 | 0.180 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2021 | 311 | 0.170 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2018 | 388 | 0.170 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2004 | 1415 | 0.170 |
Why?
|
| Gene Fusion | 1 | 2021 | 209 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 2 | 2010 | 821 | 0.170 |
Why?
|
| Capecitabine | 4 | 2016 | 388 | 0.170 |
Why?
|
| Pinocytosis | 1 | 2019 | 28 | 0.170 |
Why?
|
| Syndecan-1 | 1 | 2019 | 52 | 0.170 |
Why?
|
| Farnesyltranstransferase | 1 | 2019 | 122 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2015 | 2359 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 292 | 0.170 |
Why?
|
| Reactive Oxygen Species | 4 | 2018 | 987 | 0.170 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2019 | 87 | 0.170 |
Why?
|
| Repressor Proteins | 3 | 2023 | 1664 | 0.170 |
Why?
|
| Mitochondrial Dynamics | 1 | 2019 | 62 | 0.170 |
Why?
|
| Oncogenes | 3 | 2019 | 673 | 0.170 |
Why?
|
| Young Adult | 18 | 2018 | 21445 | 0.170 |
Why?
|
| Endoscopy | 2 | 2013 | 479 | 0.170 |
Why?
|
| Cancer Care Facilities | 2 | 2021 | 884 | 0.170 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2019 | 92 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 661 | 0.170 |
Why?
|
| Genes, p53 | 2 | 2021 | 1090 | 0.170 |
Why?
|
| Feasibility Studies | 5 | 2018 | 2292 | 0.170 |
Why?
|
| Gastrectomy | 1 | 2021 | 451 | 0.160 |
Why?
|
| Cryoprotective Agents | 1 | 2018 | 11 | 0.160 |
Why?
|
| Endometrial Neoplasms | 1 | 2008 | 1341 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 371 | 0.160 |
Why?
|
| Surgical Oncology | 1 | 2020 | 190 | 0.160 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2018 | 53 | 0.160 |
Why?
|
| Venous Thromboembolism | 2 | 2013 | 335 | 0.160 |
Why?
|
| Texas | 12 | 2018 | 6311 | 0.160 |
Why?
|
| Enzyme Inhibitors | 3 | 2021 | 1879 | 0.160 |
Why?
|
| Suture Techniques | 2 | 2015 | 319 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 164 | 0.160 |
Why?
|
| Organ Sparing Treatments | 2 | 2016 | 277 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2013 | 986 | 0.160 |
Why?
|
| DNA Damage | 3 | 2021 | 1954 | 0.160 |
Why?
|
| Intestinal Obstruction | 1 | 2020 | 202 | 0.160 |
Why?
|
| Carcinoid Tumor | 2 | 2011 | 280 | 0.150 |
Why?
|
| Disinfection | 1 | 2017 | 42 | 0.150 |
Why?
|
| Cachexia | 1 | 2019 | 161 | 0.150 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 328 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 4 | 2019 | 1443 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2008 | 272 | 0.150 |
Why?
|
| Vascular Patency | 1 | 2018 | 218 | 0.150 |
Why?
|
| Vascular Surgical Procedures | 2 | 2018 | 655 | 0.150 |
Why?
|
| Thyroidectomy | 2 | 1999 | 486 | 0.150 |
Why?
|
| Tissue Array Analysis | 6 | 2015 | 760 | 0.150 |
Why?
|
| Body Composition | 2 | 2017 | 595 | 0.150 |
Why?
|
| Walking | 1 | 2019 | 277 | 0.150 |
Why?
|
| Malate Dehydrogenase | 1 | 2017 | 21 | 0.150 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2017 | 69 | 0.150 |
Why?
|
| Sarcopenia | 2 | 2017 | 110 | 0.150 |
Why?
|
| Cryopreservation | 1 | 2018 | 175 | 0.150 |
Why?
|
| Receptors, N-Acetylglucosamine | 1 | 2016 | 2 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2023 | 2054 | 0.150 |
Why?
|
| Argininosuccinate Synthase | 1 | 2017 | 54 | 0.150 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 783 | 0.150 |
Why?
|
| Plant Lectins | 1 | 2016 | 27 | 0.140 |
Why?
|
| Precision Medicine | 2 | 2022 | 1154 | 0.140 |
Why?
|
| RNA Interference | 4 | 2021 | 1408 | 0.140 |
Why?
|
| Home Care Services | 1 | 2017 | 92 | 0.140 |
Why?
|
| Chi-Square Distribution | 6 | 2015 | 1323 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2019 | 667 | 0.140 |
Why?
|
| Cadherins | 3 | 2016 | 660 | 0.140 |
Why?
|
| Somatostatin | 1 | 2017 | 114 | 0.140 |
Why?
|
| Streptozocin | 1 | 2016 | 75 | 0.140 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 2283 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2020 | 1648 | 0.140 |
Why?
|
| Social Support | 1 | 2019 | 560 | 0.140 |
Why?
|
| Operating Rooms | 1 | 2017 | 122 | 0.140 |
Why?
|
| Caregivers | 1 | 2022 | 677 | 0.140 |
Why?
|
| Esophagectomy | 3 | 2022 | 911 | 0.140 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2016 | 111 | 0.140 |
Why?
|
| Monocytes | 1 | 2020 | 788 | 0.140 |
Why?
|
| Injections, Intravenous | 2 | 2014 | 573 | 0.140 |
Why?
|
| Stents | 3 | 2011 | 1096 | 0.140 |
Why?
|
| Obesity | 1 | 2009 | 2884 | 0.140 |
Why?
|
| Fibrinolytic Agents | 3 | 2013 | 324 | 0.140 |
Why?
|
| Splenectomy | 1 | 2016 | 158 | 0.140 |
Why?
|
| Insulinoma | 1 | 2016 | 55 | 0.140 |
Why?
|
| Splenic Neoplasms | 1 | 2016 | 119 | 0.140 |
Why?
|
| Dependovirus | 1 | 2017 | 135 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2019 | 291 | 0.140 |
Why?
|
| Blotting, Western | 5 | 2015 | 3536 | 0.140 |
Why?
|
| United States | 9 | 2021 | 15433 | 0.140 |
Why?
|
| Analysis of Variance | 3 | 2020 | 2307 | 0.140 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 493 | 0.140 |
Why?
|
| Interleukin-1alpha | 2 | 2015 | 56 | 0.130 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2015 | 93 | 0.130 |
Why?
|
| Videoconferencing | 1 | 2016 | 56 | 0.130 |
Why?
|
| Hormones | 1 | 2017 | 266 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 493 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 1248 | 0.130 |
Why?
|
| Blood Platelets | 1 | 2020 | 731 | 0.130 |
Why?
|
| Drug Synergism | 2 | 2019 | 1313 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2015 | 18 | 0.130 |
Why?
|
| Dissection | 2 | 2016 | 156 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2020 | 1234 | 0.130 |
Why?
|
| Transcriptome | 3 | 2019 | 1859 | 0.130 |
Why?
|
| Drainage | 2 | 2022 | 416 | 0.130 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 70 | 0.130 |
Why?
|
| Thyroid Neoplasms | 3 | 2003 | 1866 | 0.130 |
Why?
|
| Neoplasms | 5 | 2021 | 15193 | 0.130 |
Why?
|
| Mesoderm | 1 | 2017 | 404 | 0.130 |
Why?
|
| Health Personnel | 1 | 2020 | 625 | 0.130 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2016 | 192 | 0.130 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 249 | 0.130 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 88 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 2017 | 245 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2018 | 629 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2016 | 5437 | 0.120 |
Why?
|
| Extracellular Space | 1 | 2014 | 132 | 0.120 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2014 | 16 | 0.120 |
Why?
|
| Thrombectomy | 1 | 2015 | 158 | 0.120 |
Why?
|
| Lung Neoplasms | 6 | 2017 | 11538 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2016 | 199 | 0.120 |
Why?
|
| Perioperative Care | 1 | 2018 | 451 | 0.120 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2015 | 82 | 0.120 |
Why?
|
| Ultrasonography | 4 | 2012 | 1863 | 0.120 |
Why?
|
| Salmonella Infections | 1 | 2014 | 40 | 0.120 |
Why?
|
| Salmonella typhimurium | 1 | 2014 | 70 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2016 | 534 | 0.120 |
Why?
|
| Risk Management | 1 | 2015 | 107 | 0.120 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 131 | 0.120 |
Why?
|
| Cell Cycle | 4 | 2015 | 2084 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 481 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2018 | 785 | 0.120 |
Why?
|
| Thrombocytosis | 1 | 2015 | 121 | 0.120 |
Why?
|
| Swine | 5 | 2013 | 1541 | 0.120 |
Why?
|
| Cohort Studies | 8 | 2021 | 9244 | 0.120 |
Why?
|
| Tumor Escape | 1 | 2016 | 251 | 0.120 |
Why?
|
| Down-Regulation | 3 | 2017 | 2074 | 0.120 |
Why?
|
| Neoplasm, Residual | 3 | 2015 | 1656 | 0.120 |
Why?
|
| Sequence Deletion | 1 | 2017 | 875 | 0.120 |
Why?
|
| Organs at Risk | 1 | 2016 | 514 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 3 | 2017 | 848 | 0.120 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 170 | 0.110 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2013 | 84 | 0.110 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2013 | 47 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 7702 | 0.110 |
Why?
|
| Biological Transport | 1 | 2014 | 597 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2017 | 1506 | 0.110 |
Why?
|
| Carcinoma, Papillary | 2 | 2014 | 584 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 621 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 245 | 0.110 |
Why?
|
| Incidence | 6 | 2019 | 5673 | 0.110 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.110 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 461 | 0.110 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2014 | 168 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2016 | 810 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2020 | 1682 | 0.110 |
Why?
|
| Intracranial Embolism | 1 | 2012 | 39 | 0.110 |
Why?
|
| Head Injuries, Closed | 1 | 2012 | 45 | 0.110 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 5159 | 0.110 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 1202 | 0.110 |
Why?
|
| Adolescent | 14 | 2017 | 31252 | 0.110 |
Why?
|
| Proteomics | 2 | 2022 | 1380 | 0.110 |
Why?
|
| Clinical Clerkship | 1 | 2013 | 87 | 0.110 |
Why?
|
| Giant Cells | 1 | 2012 | 69 | 0.110 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 170 | 0.110 |
Why?
|
| Cerebral Arteries | 1 | 2012 | 73 | 0.110 |
Why?
|
| Hospital Mortality | 6 | 2018 | 1274 | 0.110 |
Why?
|
| Protein Transport | 1 | 2014 | 734 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 348 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 1586 | 0.100 |
Why?
|
| Protein Array Analysis | 1 | 2014 | 501 | 0.100 |
Why?
|
| Risk | 2 | 2020 | 1972 | 0.100 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2012 | 330 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2009 | 1533 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 4367 | 0.100 |
Why?
|
| Algorithms | 3 | 2020 | 3890 | 0.100 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 2086 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2016 | 825 | 0.100 |
Why?
|
| Elasticity | 1 | 2012 | 156 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 460 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2017 | 3101 | 0.100 |
Why?
|
| Diet, High-Fat | 1 | 2013 | 241 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2017 | 1442 | 0.100 |
Why?
|
| Environmental Monitoring | 1 | 2012 | 105 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 1073 | 0.100 |
Why?
|
| Veins | 1 | 2012 | 157 | 0.100 |
Why?
|
| Catheter Ablation | 3 | 2002 | 620 | 0.100 |
Why?
|
| RNA-Binding Proteins | 2 | 2023 | 984 | 0.100 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 167 | 0.100 |
Why?
|
| Bile | 1 | 2011 | 81 | 0.100 |
Why?
|
| Glutamine | 1 | 2013 | 299 | 0.100 |
Why?
|
| Retinal Dehydrogenase | 1 | 2011 | 91 | 0.100 |
Why?
|
| Gene Expression | 3 | 2014 | 3570 | 0.100 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 137 | 0.100 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 336 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 483 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2023 | 2803 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2013 | 4971 | 0.100 |
Why?
|
| Cardiomegaly | 1 | 2012 | 195 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 3639 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 191 | 0.100 |
Why?
|
| Fear | 1 | 2012 | 254 | 0.100 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2012 | 214 | 0.100 |
Why?
|
| Exercise | 1 | 2018 | 1183 | 0.100 |
Why?
|
| Survivors | 2 | 2016 | 1031 | 0.100 |
Why?
|
| Cell Lineage | 1 | 2013 | 668 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2012 | 250 | 0.090 |
Why?
|
| Abdomen | 1 | 2012 | 332 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2012 | 185 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2016 | 3005 | 0.090 |
Why?
|
| Blood Preservation | 1 | 2010 | 54 | 0.090 |
Why?
|
| Cell Nucleolus | 1 | 2010 | 89 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2017 | 2203 | 0.090 |
Why?
|
| Odds Ratio | 5 | 2016 | 2316 | 0.090 |
Why?
|
| Blood Component Transfusion | 1 | 2010 | 89 | 0.090 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2010 | 35 | 0.090 |
Why?
|
| Age Factors | 5 | 2018 | 5377 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 590 | 0.090 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2023 | 159 | 0.090 |
Why?
|
| Quality of Life | 2 | 2016 | 4532 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 132 | 0.090 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2011 | 221 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2010 | 170 | 0.090 |
Why?
|
| Databases, Factual | 4 | 2018 | 2218 | 0.090 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2009 | 21 | 0.090 |
Why?
|
| Brain Ischemia | 1 | 2012 | 292 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 487 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2016 | 992 | 0.090 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2011 | 170 | 0.090 |
Why?
|
| Telemedicine | 1 | 2016 | 471 | 0.090 |
Why?
|
| Receptor, trkB | 1 | 2009 | 53 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 2403 | 0.090 |
Why?
|
| Cyst Fluid | 1 | 2009 | 21 | 0.090 |
Why?
|
| Heart Atria | 1 | 2012 | 352 | 0.090 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2009 | 34 | 0.090 |
Why?
|
| Plasma | 1 | 2010 | 158 | 0.090 |
Why?
|
| Biocatalysis | 2 | 2021 | 63 | 0.090 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2009 | 79 | 0.090 |
Why?
|
| Sjogren's Syndrome | 1 | 2010 | 102 | 0.090 |
Why?
|
| Aftercare | 1 | 2011 | 259 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 3 | 2018 | 1077 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 671 | 0.090 |
Why?
|
| Cholestasis | 1 | 2011 | 203 | 0.080 |
Why?
|
| Cisplatin | 5 | 2014 | 2432 | 0.080 |
Why?
|
| Diagnostic Imaging | 3 | 2012 | 1162 | 0.080 |
Why?
|
| Isoenzymes | 1 | 2011 | 614 | 0.080 |
Why?
|
| Cytodiagnosis | 2 | 2014 | 220 | 0.080 |
Why?
|
| Induction Chemotherapy | 3 | 2016 | 669 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2011 | 1385 | 0.080 |
Why?
|
| Recurrence | 3 | 2014 | 4758 | 0.080 |
Why?
|
| Macrophages, Peritoneal | 1 | 2008 | 66 | 0.080 |
Why?
|
| Neurilemmoma | 1 | 2009 | 127 | 0.080 |
Why?
|
| Tissue Banks | 1 | 2008 | 55 | 0.080 |
Why?
|
| Reoperation | 4 | 2015 | 1382 | 0.080 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2009 | 115 | 0.080 |
Why?
|
| Students, Medical | 1 | 2013 | 399 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 2104 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2008 | 133 | 0.080 |
Why?
|
| Gene Silencing | 2 | 2014 | 837 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 598 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2012 | 607 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2017 | 1763 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2011 | 747 | 0.080 |
Why?
|
| Parathyroidectomy | 1 | 2009 | 203 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 4654 | 0.080 |
Why?
|
| Mice, Transgenic | 5 | 2013 | 4143 | 0.080 |
Why?
|
| Parathyroid Neoplasms | 1 | 2009 | 185 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 761 | 0.080 |
Why?
|
| Cyclins | 2 | 1999 | 456 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 2027 | 0.070 |
Why?
|
| Microbubbles | 1 | 2007 | 14 | 0.070 |
Why?
|
| Lymphocyte Count | 2 | 2020 | 486 | 0.070 |
Why?
|
| Pedigree | 2 | 2009 | 1890 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2011 | 889 | 0.070 |
Why?
|
| Anastomotic Leak | 2 | 2020 | 71 | 0.070 |
Why?
|
| Fibrosis | 3 | 2016 | 793 | 0.070 |
Why?
|
| Platelet Count | 2 | 2020 | 490 | 0.070 |
Why?
|
| Diagnosis, Differential | 6 | 2014 | 4744 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2010 | 1152 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2017 | 2669 | 0.070 |
Why?
|
| Patient Discharge | 3 | 2016 | 661 | 0.070 |
Why?
|
| Genetic Testing | 2 | 2009 | 1589 | 0.070 |
Why?
|
| Octreotide | 2 | 2020 | 118 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 3154 | 0.070 |
Why?
|
| In Vitro Techniques | 4 | 2011 | 1618 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2006 | 212 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2008 | 299 | 0.070 |
Why?
|
| Colostomy | 1 | 2005 | 70 | 0.070 |
Why?
|
| Oxidative Phosphorylation | 2 | 2019 | 253 | 0.070 |
Why?
|
| RNA, Catalytic | 1 | 2005 | 37 | 0.070 |
Why?
|
| Internship and Residency | 2 | 2015 | 1375 | 0.070 |
Why?
|
| Ileostomy | 1 | 2005 | 46 | 0.070 |
Why?
|
| Ketoglutaric Acids | 2 | 2017 | 38 | 0.070 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2005 | 8 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2019 | 5270 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2330 | 0.070 |
Why?
|
| Radiography, Thoracic | 2 | 2013 | 462 | 0.070 |
Why?
|
| Colonic Diseases | 1 | 2005 | 71 | 0.060 |
Why?
|
| Peptides | 1 | 2011 | 1479 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 1283 | 0.060 |
Why?
|
| Peptic Ulcer | 1 | 2005 | 140 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2008 | 402 | 0.060 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2009 | 469 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 2 | 2023 | 492 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2021 | 5710 | 0.060 |
Why?
|
| Up-Regulation | 4 | 2016 | 2450 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 2341 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2016 | 665 | 0.060 |
Why?
|
| Hysterectomy | 1 | 2008 | 611 | 0.060 |
Why?
|
| Glycolysis | 2 | 2019 | 519 | 0.060 |
Why?
|
| Proteins | 2 | 2021 | 1963 | 0.060 |
Why?
|
| Stroke | 1 | 2012 | 1144 | 0.060 |
Why?
|
| Adenoma | 1 | 2009 | 716 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2005 | 259 | 0.060 |
Why?
|
| Pyrroles | 1 | 2008 | 576 | 0.060 |
Why?
|
| Transfection | 3 | 2016 | 2944 | 0.060 |
Why?
|
| Logistic Models | 3 | 2016 | 3441 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 4314 | 0.060 |
Why?
|
| SOS1 Protein | 1 | 2023 | 2 | 0.060 |
Why?
|
| Anastomosis, Surgical | 1 | 2005 | 371 | 0.060 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2003 | 25 | 0.060 |
Why?
|
| Base Sequence | 3 | 2017 | 4917 | 0.060 |
Why?
|
| Focal Adhesions | 1 | 2003 | 45 | 0.060 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2005 | 315 | 0.060 |
Why?
|
| Cell Line, Transformed | 2 | 2014 | 394 | 0.060 |
Why?
|
| RNA Splicing Factors | 1 | 2023 | 153 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2003 | 172 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2020 | 500 | 0.060 |
Why?
|
| Radioisotopes | 1 | 2003 | 177 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 2 | 2017 | 651 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 1678 | 0.050 |
Why?
|
| Hypertension | 1 | 2012 | 1503 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 1085 | 0.050 |
Why?
|
| Radiotherapy Dosage | 3 | 2016 | 3842 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2005 | 1053 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2016 | 3341 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2005 | 771 | 0.050 |
Why?
|
| Laparoscopes | 1 | 2001 | 10 | 0.050 |
Why?
|
| Man-Machine Systems | 1 | 2001 | 8 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 660 | 0.050 |
Why?
|
| Protein Subunits | 2 | 2016 | 274 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2018 | 1996 | 0.050 |
Why?
|
| Calcitonin | 2 | 1999 | 186 | 0.050 |
Why?
|
| Radiography | 3 | 2015 | 1904 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2021 | 53 | 0.050 |
Why?
|
| Contrast Media | 3 | 2013 | 1472 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2023 | 370 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2022 | 148 | 0.050 |
Why?
|
| Platinum | 1 | 2022 | 138 | 0.050 |
Why?
|
| Epirubicin | 1 | 2021 | 157 | 0.050 |
Why?
|
| Task Performance and Analysis | 1 | 2001 | 136 | 0.050 |
Why?
|
| Emergencies | 1 | 2003 | 202 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2023 | 842 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2017 | 1008 | 0.050 |
Why?
|
| Neurons | 1 | 2012 | 2287 | 0.050 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2003 | 262 | 0.050 |
Why?
|
| Homologous Recombination | 1 | 2022 | 185 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2019 | 5637 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1217 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 3976 | 0.050 |
Why?
|
| Colectomy | 1 | 2022 | 288 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 2139 | 0.050 |
Why?
|
| Organoplatinum Compounds | 2 | 2015 | 702 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 233 | 0.050 |
Why?
|
| Precancerous Conditions | 3 | 2010 | 1058 | 0.050 |
Why?
|
| Tissue Culture Techniques | 1 | 2020 | 114 | 0.050 |
Why?
|
| Functional Laterality | 1 | 2001 | 316 | 0.050 |
Why?
|
| Histocytochemistry | 1 | 2020 | 185 | 0.050 |
Why?
|
| DNA Primers | 2 | 2014 | 1399 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 521 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2022 | 575 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2014 | 528 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 980 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 268 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2017 | 1756 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2022 | 400 | 0.040 |
Why?
|
| Wnt-5a Protein | 1 | 2019 | 45 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2003 | 2508 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2000 | 154 | 0.040 |
Why?
|
| Geography, Medical | 1 | 2019 | 21 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2020 | 208 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2019 | 54 | 0.040 |
Why?
|
| Dynamins | 1 | 2019 | 74 | 0.040 |
Why?
|
| Quinazolinones | 1 | 2019 | 51 | 0.040 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2019 | 32 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 2314 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2008 | 1471 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2020 | 191 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2015 | 1764 | 0.040 |
Why?
|
| Florida | 1 | 2019 | 113 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5319 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 360 | 0.040 |
Why?
|
| Nomograms | 1 | 2021 | 313 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2019 | 122 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 684 | 0.040 |
Why?
|
| Sepsis | 2 | 2015 | 652 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 1165 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2022 | 450 | 0.040 |
Why?
|
| Oncologists | 1 | 2021 | 134 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 441 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2021 | 1824 | 0.040 |
Why?
|
| Micelles | 1 | 2018 | 34 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 1546 | 0.040 |
Why?
|
| Mycoplasma hyorhinis | 1 | 2017 | 5 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2020 | 574 | 0.040 |
Why?
|
| Xenon | 1 | 2017 | 19 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 53 | 0.040 |
Why?
|
| Gammaproteobacteria | 1 | 2017 | 19 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2017 | 46 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 133 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 925 | 0.040 |
Why?
|
| Oncogene Protein p55(v-myc) | 1 | 2017 | 19 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2017 | 69 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 95 | 0.040 |
Why?
|
| Digoxin | 1 | 2017 | 63 | 0.040 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2017 | 32 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 561 | 0.040 |
Why?
|
| Child | 4 | 2023 | 29154 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2019 | 336 | 0.040 |
Why?
|
| Pregnancy Proteins | 1 | 2017 | 44 | 0.040 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2017 | 111 | 0.040 |
Why?
|
| Pheochromocytoma | 1 | 1999 | 281 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 92 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 343 | 0.040 |
Why?
|
| Anthropometry | 1 | 2017 | 269 | 0.040 |
Why?
|
| Taxoids | 1 | 2000 | 967 | 0.040 |
Why?
|
| Transaminases | 1 | 2017 | 76 | 0.040 |
Why?
|
| NADP | 1 | 2017 | 96 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 677 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2017 | 142 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2017 | 110 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 344 | 0.040 |
Why?
|
| Carbon | 1 | 2017 | 149 | 0.040 |
Why?
|
| SMARCB1 Protein | 1 | 2017 | 109 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 2315 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2017 | 136 | 0.040 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2017 | 94 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 624 | 0.040 |
Why?
|
| Cattle | 1 | 2018 | 783 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2016 | 61 | 0.040 |
Why?
|
| Polymers | 1 | 2018 | 223 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 226 | 0.030 |
Why?
|
| Motivation | 1 | 2019 | 499 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 323 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2015 | 21 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 5539 | 0.030 |
Why?
|
| Pyrimidines | 2 | 2019 | 3518 | 0.030 |
Why?
|
| Breath Holding | 1 | 2015 | 44 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 169 | 0.030 |
Why?
|
| Lentivirus | 1 | 2016 | 169 | 0.030 |
Why?
|
| Pancreatitis, Chronic | 1 | 2016 | 116 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2015 | 84 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 585 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 363 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2015 | 103 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2017 | 204 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2016 | 392 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2015 | 102 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2017 | 575 | 0.030 |
Why?
|
| Genes, myc | 1 | 2017 | 358 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 690 | 0.030 |
Why?
|
| Appendiceal Neoplasms | 1 | 2017 | 234 | 0.030 |
Why?
|
| Anxiety | 1 | 2022 | 1179 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6009 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1999 | 489 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2018 | 519 | 0.030 |
Why?
|
| Mosaicism | 1 | 2017 | 272 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 597 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 603 | 0.030 |
Why?
|
| Hypertension, Portal | 1 | 2015 | 124 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2014 | 52 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 191 | 0.030 |
Why?
|
| Wound Healing | 1 | 2020 | 815 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2018 | 1643 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 1085 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 5687 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 886 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 409 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 752 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2013 | 61 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 4638 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 395 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 671 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 2171 | 0.030 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 475 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2013 | 68 | 0.030 |
Why?
|
| Glutamate Dehydrogenase | 1 | 2013 | 14 | 0.030 |
Why?
|
| Vipoma | 1 | 2013 | 17 | 0.030 |
Why?
|
| Choledochostomy | 1 | 2013 | 9 | 0.030 |
Why?
|
| Pancreaticojejunostomy | 1 | 2013 | 14 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 756 | 0.030 |
Why?
|
| Gastrinoma | 1 | 2013 | 25 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 347 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2011 | 3033 | 0.030 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 86 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 304 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2013 | 257 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 1290 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 153 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 510 | 0.030 |
Why?
|
| Gastric Emptying | 1 | 2013 | 94 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2012 | 76 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2013 | 85 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 1350 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2016 | 492 | 0.030 |
Why?
|
| Nervous System | 1 | 2013 | 165 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2022 | 16273 | 0.030 |
Why?
|
| Japan | 1 | 2013 | 227 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 702 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2014 | 262 | 0.030 |
Why?
|
| Comprehension | 1 | 2013 | 120 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 752 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 111 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 108 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 938 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 2370 | 0.030 |
Why?
|
| Office Visits | 1 | 2013 | 97 | 0.030 |
Why?
|
| Mesothelioma | 1 | 2017 | 544 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2013 | 229 | 0.030 |
Why?
|
| Gastric Bypass | 1 | 2013 | 81 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2012 | 129 | 0.030 |
Why?
|
| Markov Chains | 1 | 2013 | 175 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 120 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 221 | 0.030 |
Why?
|
| Liver | 1 | 2002 | 2961 | 0.030 |
Why?
|
| Sequestosome-1 Protein | 1 | 2012 | 39 | 0.030 |
Why?
|
| Epithelium | 1 | 2014 | 720 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2013 | 232 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2014 | 382 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 1489 | 0.030 |
Why?
|
| Cell Division | 3 | 2003 | 2489 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 2819 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 100 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2012 | 163 | 0.030 |
Why?
|
| Lysosomes | 1 | 2014 | 347 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 665 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2003 | 3230 | 0.030 |
Why?
|
| Carcinogenicity Tests | 1 | 2011 | 70 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 250 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 1014 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 2011 | 159 | 0.030 |
Why?
|
| Adiposity | 1 | 2013 | 237 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2011 | 110 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 756 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 298 | 0.020 |
Why?
|
| CD24 Antigen | 1 | 2011 | 85 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 2170 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 103 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 717 | 0.020 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 403 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2012 | 272 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2012 | 246 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 15694 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 902 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 362 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2010 | 136 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 414 | 0.020 |
Why?
|
| Dyspnea | 1 | 2013 | 416 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 1265 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2011 | 249 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 1270 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 915 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2010 | 171 | 0.020 |
Why?
|
| Body Weight | 1 | 2014 | 1293 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2010 | 193 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 672 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 2992 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 472 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 234 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 3438 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2013 | 6100 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 612 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 634 | 0.020 |
Why?
|
| Aspirin | 1 | 2012 | 455 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 342 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2009 | 117 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2009 | 222 | 0.020 |
Why?
|
| Imidazoles | 1 | 2014 | 999 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 1399 | 0.020 |
Why?
|
| Hyperparathyroidism | 1 | 2009 | 93 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 2009 | 127 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2011 | 478 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 749 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 705 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 1999 | 3343 | 0.020 |
Why?
|
| Ribonucleotide Reductases | 1 | 2008 | 51 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 467 | 0.020 |
Why?
|
| Anoikis | 1 | 2008 | 63 | 0.020 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2008 | 42 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2008 | 89 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2008 | 157 | 0.020 |
Why?
|
| Homeostasis | 1 | 2013 | 950 | 0.020 |
Why?
|
| Curriculum | 1 | 2013 | 860 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2291 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1493 | 0.020 |
Why?
|
| Endoglin | 1 | 2007 | 43 | 0.020 |
Why?
|
| Carcinoma | 1 | 1998 | 2578 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 814 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5047 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4320 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 1304 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 2927 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 1688 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3472 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 1489 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 3569 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2007 | 333 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 4113 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 2173 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 1544 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 2003 | 57 | 0.010 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2003 | 18 | 0.010 |
Why?
|
| Paxillin | 1 | 2003 | 30 | 0.010 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2003 | 27 | 0.010 |
Why?
|
| Inflammation | 1 | 2013 | 2522 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2009 | 795 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2005 | 397 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 189 | 0.010 |
Why?
|
| Actin Cytoskeleton | 1 | 2003 | 82 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 2518 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 862 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 1021 | 0.010 |
Why?
|
| Constriction | 1 | 2002 | 55 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 2003 | 126 | 0.010 |
Why?
|
| Cytokines | 1 | 2012 | 2809 | 0.010 |
Why?
|
| Muscle Neoplasms | 1 | 2003 | 109 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2003 | 161 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2003 | 202 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2003 | 542 | 0.010 |
Why?
|
| Leiomyoma | 1 | 2003 | 145 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2005 | 605 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2003 | 227 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2009 | 1818 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 2003 | 223 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 869 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 3552 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 5114 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2000 | 64 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 608 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 3251 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2001 | 286 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1999 | 264 | 0.010 |
Why?
|
| Random Allocation | 1 | 2001 | 703 | 0.010 |
Why?
|
| Probability | 1 | 2001 | 866 | 0.010 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 1999 | 53 | 0.010 |
Why?
|
| Family Health | 1 | 1999 | 325 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 3719 | 0.010 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 1999 | 115 | 0.010 |
Why?
|
| Axilla | 1 | 2000 | 902 | 0.010 |
Why?
|
| Neck Dissection | 1 | 1999 | 290 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 3869 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 1204 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2000 | 876 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 1363 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2003 | 882 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 3001 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1994 | 200 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1994 | 331 | 0.010 |
Why?
|
| Molecular Biology | 1 | 1994 | 176 | 0.010 |
Why?
|